Provided by Tiger Trade Technology Pte. Ltd.

AstraZeneca PLC

160.12
+1.510.95%
Post-market: 161.000.8800+0.55%16:35 EDT
Volume:2.36M
Turnover:378.21M
Market Cap:248.35B
PE:23.97
High:161.29
Open:159.12
Low:158.53
Close:158.61
52wk High:212.71
52wk Low:153.41
Shares:1.55B
Float Shares:1.50B
Volume Ratio:0.91
T/O Rate:0.16%
Dividend:3.17
Dividend Rate:1.98%
EPS(TTM):6.68
EPS(LYR):6.54
ROE:21.96%
ROA:8.21%
PB:4.94
PE(LYR):24.48

Loading ...

Sector Update: Healthcare

MT Newswires Live
·
Oct 03

AstraZeneca PLC Stock Falls Friday, Underperforms Market

Dow Jones
·
Oct 03

Summit Therapeutics enters trial collaboration with AstraZeneca, Daiichi Sankyo

TIPRANKS
·
Oct 02

Novartis Bets $7.8 Billion On MRNA Beyond Vaccines

Options & Short Sell
·
Oct 02

Barclays Keeps Their Buy Rating on AstraZeneca (AZN)

TIPRANKS
·
Oct 02

AstraZeneca PLC Stock Falls Wednesday, Underperforms Market

Dow Jones
·
Oct 01

AstraZeneca Hedges Threat to Oncology Portfolio

Dow Jones
·
Sep 30

Bernstein Remains a Buy on AstraZeneca (AZN)

TIPRANKS
·
Sep 30

Premarket: Nasdaq Futures Rise 0.45% as Traders Eye Trump AI Luncheon

Deep News
·
Sep 29

Top Premarket Gainers

MT Newswires Live
·
Sep 29

J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)

TIPRANKS
·
Sep 29

RBC Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)

TIPRANKS
·
Sep 29

AstraZeneca Dips Toes in Emerging Class of Cancer Drugs

Dow Jones
·
Sep 29

Hutchmed Lung-Cancer Fighting Drug Submitted to FDA for Approval

MT Newswires Live
·
Sep 29

$20 Billion In Deals And Counting: Lilly's CEO Targets The "White Space" Of Science For Larger M&A

Options & Short Sell
·
Sep 29

AstraZeneca Broadens Oncology Portfolio Through Summit Deal

Dow Jones
·
Sep 29

AstraZeneca To Invest $2 Billion In Summit And Co-Develop Drugs; Shares Jump After Hours

Options & Short Sell
·
Sep 29

Hutchmed says AstraZeneca submits NDA for ORPATHYS+TAGRISSO in NSCLC

TIPRANKS
·
Sep 29

AstraZeneca to Invest $2 Billion in Summit Therapeutics for Cancer Drug Tie-up

Reuters
·
Sep 29

Stocks to Watch: Summit Therapeutics, Sangoma, Navitas

Dow Jones
·
Sep 29